Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

NCT01514188 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT01514188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01514188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 11, 2012
Completion date
December 15, 2014
Enrollment
126 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced soft tissue sarcoma, metastatic soft tissue sarcoma, unresectable soft tissue sarcoma